• EACH LIFE IS UNIQUE

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

Watch the video

PRODUCTS

Our proprietary platform technology and know-how allow us to extract and purify protein therapeutics from human plasma.

PIPELINE

Kamada’s Inhaled AAT has the potential of becoming a transformational next- generation augmentation therapy for Alpha-1 Antitrypsin Deficiency patients.

ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION

Watch the video

The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions.

This video illustrates the mechanism of action of AAT, and its possible therapeutic effects.

  • Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.

  • The allogeneic transplantation of hematopoietic cells (HCT) is a well-established treatment for hematologic diseases that cannot be cured with conventional treatments.The most common life-threatening complication is Graft Versus Host Disease (GVHD).

  • MORE
    THERAPEUTIC
    FOCUS
    AREAS